Cubist Pharmaceuticals Management Discusses Q2 2012 Results - Earnings Call Transcript

Cubist Pharmaceuticals (CBST)

Q2 2012 Earnings Call

July 19, 2012 5:00 pm ET


Eileen C. McIntyre - Senior Director of Investor Relations

Michael W. Bonney - Chief Executive Officer and Director

David W. J. McGirr - Chief Financial Officer, Principal Accounting Officer and Senior Vice President

Robert J. Perez - President and Chief Operating Officer

Steven C. Gilman - Chief Scientific Officer and Executive Vice President of Research & Development

Gregory Stea - Senior Vice President of Commercial Operations


Mario V. Corso - Caris & Company, Inc., Research Division

Thomas J. Russo - Robert W. Baird & Co. Incorporated, Research Division

Eun K. Yang - Jefferies & Company, Inc., Research Division

Steve Byrne - BofA Merrill Lynch, Research Division

Alan Carr - Needham & Company, LLC, Research Division

Adnan S. Butt - RBC Capital Markets, LLC, Research Division

James F. Molloy - ThinkEquity LLC, Research Division

Howard Liang - Leerink Swann LLC, Research Division

Stephen Willey - Stifel, Nicolaus & Co., Inc., Research Division



Good day. My name is Nikki, and I will be your events specialist today. At this time, I would like to welcome everyone to the Cubist Pharmaceuticals Second Quarter Earnings Call. [Operator Instructions] At this time, I would like to turn today's program over to Eileen McIntyre. Eileen, you may begin.

Eileen C. McIntyre

Good afternoon, and thank you for joining us for our review of Second Quarter 2012 Business Performance and Financial Results of Cubist Pharmaceuticals. Before introducing our speakers, I will read the safe harbor statement and describe the context for use of non-GAAP financial measures.

If you liked this article you might like

Cubist Pharmaceuticals (CBST) Hits New Lifetime High

Trade-Ideas: Cubist Pharmaceuticals (CBST) Is Today's New Lifetime High Stock

Orphan Drug Company NPS Pharmaceuticals May Find Few Buyers

Jim Cramer on the Markets: Some Stocks You Just Can't Ignore

Cubist Pharmaceuticals (CBST): Today's Pre-Market Leader Stock